DK2614835T3 - Vaccination med flere clader af H5 influenzavirus A - Google Patents

Vaccination med flere clader af H5 influenzavirus A Download PDF

Info

Publication number
DK2614835T3
DK2614835T3 DK12198671T DK12198671T DK2614835T3 DK 2614835 T3 DK2614835 T3 DK 2614835T3 DK 12198671 T DK12198671 T DK 12198671T DK 12198671 T DK12198671 T DK 12198671T DK 2614835 T3 DK2614835 T3 DK 2614835T3
Authority
DK
Denmark
Prior art keywords
vaccination
influenza virus
multiple clades
clades
influenza
Prior art date
Application number
DK12198671T
Other languages
English (en)
Inventor
Audino Podda
Rino Rappuoli
Original Assignee
Seqirus Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39638239&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2614835(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Seqirus Uk Ltd filed Critical Seqirus Uk Ltd
Application granted granted Critical
Publication of DK2614835T3 publication Critical patent/DK2614835T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK12198671T 2007-11-26 2008-11-25 Vaccination med flere clader af H5 influenzavirus A DK2614835T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US433407P 2007-11-26 2007-11-26
GBGB0810305.3A GB0810305D0 (en) 2008-06-05 2008-06-05 Influenza vaccination
EP08854338.4A EP2211901B2 (en) 2007-11-26 2008-11-25 Vaccination with multiple clades of h5 influenza a virus

Publications (1)

Publication Number Publication Date
DK2614835T3 true DK2614835T3 (da) 2019-11-25

Family

ID=39638239

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08854338.4T DK2211901T3 (da) 2007-11-26 2008-11-25 Vaccination med multiple clader af h5-influenza-a-virus
DK12198671T DK2614835T3 (da) 2007-11-26 2008-11-25 Vaccination med flere clader af H5 influenzavirus A

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK08854338.4T DK2211901T3 (da) 2007-11-26 2008-11-25 Vaccination med multiple clader af h5-influenza-a-virus

Country Status (17)

Country Link
US (1) US9669088B2 (da)
EP (2) EP2614835B1 (da)
JP (3) JP5957176B2 (da)
KR (2) KR20160079140A (da)
CN (1) CN101969995A (da)
AU (2) AU2008331238B2 (da)
CA (1) CA2706619C (da)
CY (1) CY1114762T1 (da)
DK (2) DK2211901T3 (da)
ES (2) ES2417495T5 (da)
GB (1) GB0810305D0 (da)
HR (1) HRP20130634T1 (da)
NZ (1) NZ585674A (da)
PL (2) PL2211901T5 (da)
PT (2) PT2211901E (da)
SI (1) SI2211901T1 (da)
WO (1) WO2009068992A1 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11707520B2 (en) * 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
GB0905570D0 (en) * 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
JP5712126B2 (ja) 2008-06-25 2015-05-07 ノバルティス アーゲー 遅延型追加刺激免疫処置に対する迅速な応答
WO2010103022A2 (en) * 2009-03-12 2010-09-16 Sanofi Pasteur Oil-in-water adjuvanted influenza vaccine
EP3009145A1 (en) 2009-03-30 2016-04-20 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
AU2010254136B2 (en) 2009-05-26 2016-09-29 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
CA2790380A1 (en) 2010-02-18 2011-08-25 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
EP3248615A1 (en) 2010-03-30 2017-11-29 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
ES2739711T3 (es) 2010-07-22 2020-02-03 John W Schrader Anticuerpo de protección cruzada contra la infección por el virus de la gripe
CN107281478B (zh) * 2010-07-23 2022-04-01 诺瓦瓦克斯公司 流感疫苗
WO2012050229A1 (ja) 2010-10-15 2012-04-19 財団法人東京都医学総合研究所 新型インフルエンザウイルス由来ヘマグルチニンタンパク質遺伝子を有する組換えワクシニアウイルス
IN2014CN02114A (da) 2011-09-20 2015-05-29 Sinai School Medicine
WO2013075266A1 (en) * 2011-11-23 2013-05-30 Vacdiagn Biotechnology Co., Ltd. Immune methods against influenza viruses and combinatorial vaccines thereof
EA201591164A1 (ru) 2012-12-18 2015-11-30 Икан Скул Оф Медсин Эт Маунт Синай Вакцины против вируса гриппа и их применение
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
EP3247389A4 (en) 2015-01-23 2019-10-30 Icahn School of Medicine at Mount Sinai INFLUENZAVIRUSSCHUTZIMPFPLÄNE
CN105288609A (zh) * 2015-10-16 2016-02-03 天津瑞普生物技术股份有限公司 一种基于杆状病毒表达系统的禽流感病毒疫苗制备方法
EP4233898A3 (en) * 2016-05-04 2023-11-01 CureVac SE Influenza mrna vaccines
CA3023143A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
WO2019035972A1 (en) * 2017-08-16 2019-02-21 Georgia State University Research Foundation, Inc. SEQUENTIAL IMMUNIZATIONS WITH HIV-1 ENV VIRUS TYPE PARTICLES
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
EP3810634A4 (en) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
MX2019014943A (es) 2018-12-12 2020-08-06 Cambridge Tech Llc Vacuna universal contra la gripe.
EP3959216A4 (en) 2019-04-24 2023-01-11 Icahn School of Medicine at Mount Sinai ANTI-INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF
CN113842455B (zh) * 2021-08-27 2022-05-13 北京康乐卫士生物技术股份有限公司 一种新型冠状病毒疫苗的佐剂及其应用和新型冠状病毒二价重组疫苗

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4060082A (en) 1976-08-16 1977-11-29 Mpl, Inc. Dual-ingredient medication dispenser
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NZ241926A (en) 1988-08-25 1993-08-26 Liposome Co Inc Immunisation dosage form comprising a salt of an organic acid derivative of a sterol and an antigen
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
US5658731A (en) 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
CA2289219C (en) 1991-03-01 2003-05-20 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1h-imidazo[4,5-c]quinolin-4-amines
JPH0614756Y2 (ja) 1991-06-26 1994-04-20 株式会社アルテ 組み立て式の２室式容器兼用注射器
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
MA22842A1 (fr) 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
DK0671948T3 (da) 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
ATE157882T1 (de) 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
EP0708772B1 (en) 1993-07-15 2000-08-23 Minnesota Mining And Manufacturing Company IMIDAZO [4,5-c]PYRIDIN-4-AMINES
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
PT733113E (pt) 1994-01-11 2007-08-10 Vlaams Interuniv Inst Biotech Vacina contra a gripe
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US5496284A (en) 1994-09-27 1996-03-05 Waldenburg; Ottfried Dual-chamber syringe & method
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
GB9503863D0 (en) 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
AU3186297A (en) 1996-07-05 1998-02-02 Debiotech S.A. Dual-chamber syringe for mixing two substances prior to injection
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
WO1998046262A1 (en) 1997-04-16 1998-10-22 Connaught Laboratories, Inc. Anti-influenza compositions supplemented with neuraminidase
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
US5971953A (en) 1998-01-09 1999-10-26 Bachynsky; Nicholas Dual chamber syringe apparatus
WO1999017820A1 (en) 1997-10-03 1999-04-15 Texas Pharmaceuticals, Inc. Improved dual chamber syringe apparatus
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
IL138000A0 (en) 1998-04-09 2001-10-31 Smithkline Beecham Biolog Adjuvant compositions
HK1039072A1 (zh) 1998-05-07 2002-04-12 科里克萨有限公司 佐剂组合物及其使用方法
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
DE19835749C1 (de) 1998-08-07 2000-02-03 Dieter Perthes Fertig-Spritze für nicht-stabile Arzneimittel
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
CA2361421A1 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
DE60039198D1 (de) 1999-03-26 2008-07-24 Vical Inc Adjuvanszusammensetzungen zur Erhöhung der Immunantwort bezüglich Polynukleotid-basierenden Impfstoffen
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
ES2278621T5 (es) 1999-07-14 2011-02-02 Mount Sinai School Of Medicine Of New York University Reconstrucción in vitro de virus arn segmentados de polaridad negativa.
TR200200776T2 (tr) 1999-09-24 2002-06-21 Smithkline Beecham Biologicals S.A. Burun içi grip virüsü aşısı.
CZ20021043A3 (cs) 1999-09-24 2002-08-14 Smithkline Beecham Biologicals S. A. Pouľití kombinace polyoxyethylensorbitanového esteru a oktoxynolu pro výrobu pomocného prostředku
KR20020048942A (ko) 1999-09-24 2002-06-24 장 스테판느 폴리옥시에틸렌 알킬 에테르 또는 에스테르 및 하나이상의 비이온성 계면활성제를 포함하는 애쥬번트
SK287400B6 (sk) 1999-09-25 2010-08-09 University Of Iowa Research Foundation Prostriedok s obsahom imunostimulačnej nukleovej kyseliny a jeho použitie na stimuláciu imunitnej reakcie
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
EP1311288A1 (en) 2000-01-20 2003-05-21 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
JP4698112B2 (ja) 2000-03-03 2011-06-08 一般財団法人化学及血清療法研究所 無血清培養かつ浮遊培養可能な細胞及び当該細胞を用いたワクチン用ウイルスの製造法
MXPA02010642A (es) 2000-04-28 2004-05-17 St Jude Children S Res Hospital Sistema de transfeccion de adn para la generacion de virus de influenza infeccioso.
FR2808803B1 (fr) 2000-05-11 2004-12-10 Agronomique Inst Nat Rech Cellules es modifiees et gene specifique de cellules es
EP1313734B1 (en) 2000-09-01 2009-11-11 Novartis Vaccines and Diagnostics, Inc. Aza heterocyclic derivatives and their therapeutic use
CZ304344B6 (cs) 2000-09-11 2014-03-19 Novartis Vaccines & Diagnostics, Inc. Chinolinonový derivát a jeho použití a farmaceutický prostředek s obsahem tohoto derivátu
AU9475001A (en) 2000-09-26 2002-04-08 Hybridon Inc Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
ATE503493T1 (de) 2001-02-23 2011-04-15 Glaxosmithkline Biolog Sa Influenza vakzinzusammensetzungen zur intradermaler verabreichung
JP2004536785A (ja) 2001-02-23 2004-12-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規なワクチン
DE60238471D1 (de) 2001-03-09 2011-01-13 Id Biomedical Corp Quebec Proteosom-liposaccharid-vakzine-adjuvans
CA2439111A1 (en) 2001-04-05 2002-10-17 Chiron Corporation Mucosal boosting following parenteral priming
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
DE10144903A1 (de) 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
FR2832423B1 (fr) 2001-11-22 2004-10-08 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
EA008380B1 (ru) 2001-11-27 2007-04-27 Анадис Фармасьютикалз, Инк. 3-β-D-РИБОФУРАНОЗИЛТИАЗОЛО[4,5-d]ПИРИМИДИННУКЛЕОЗИДЫ И ИХ ПРИМЕНЕНИЯ
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
NZ535985A (en) 2002-03-29 2007-04-27 Chiron Corp Substituted benzazoles and use thereof as RAF kinase inhibitors
EP1511746A2 (en) 2002-05-29 2005-03-09 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
WO2003105769A2 (en) 2002-06-13 2003-12-24 New York University Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
AU2003268184A1 (en) 2002-08-23 2004-03-11 Chiron Corporation Pyrrole based inhibitors of glycogen synthase kinase 3
CA2511646A1 (en) 2002-12-27 2004-07-22 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
ES2391770T3 (es) 2003-01-21 2012-11-29 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos de triptantrina para la potenciación inmune
GB0301554D0 (en) 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
US8080255B2 (en) 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
RU2236257C1 (ru) 2003-09-15 2004-09-20 Косяков Константин Сергеевич Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами
US7771726B2 (en) 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
WO2005107797A1 (en) 2004-03-09 2005-11-17 Chiron Corporation Influenza virus vaccines
CN1933862A (zh) 2004-03-23 2007-03-21 尼普洛株式会社 预充式注射器
CN1964626A (zh) 2004-03-31 2007-05-16 纽约大学 新型合成c－糖脂、其合成及其治疗传染病、癌症和自身免疫性疾病的用途
AU2005230708B2 (en) 2004-04-05 2009-01-15 Zoetis Services Llc Microfluidized oil-in-water emulsions and vaccine compositions
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
NZ551640A (en) 2004-05-20 2010-05-28 Id Biomedical Corp Process for the production of an influenza vaccine
JP2008504292A (ja) 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 免疫増強用の化合物
JP2008512443A (ja) 2004-09-09 2008-04-24 カイロン ベーリング ゲーエムベーハー アンド カンパニー インフルエンザワクチンに関連する潜在的医原性リスクの減少
TWI365074B (en) * 2004-10-07 2012-06-01 Wyeth Corp Multivalent avian influenza vaccines
WO2006050394A2 (en) 2004-11-01 2006-05-11 Novartis Vaccines And Diagnostics Inc. Combination approaches for generating immune responses
ATE547511T1 (de) 2004-12-23 2012-03-15 Medimmune Llc Nichttumorbildende mdck-zellinie zur vermehrung von viren
EP2295542B1 (en) 2004-12-24 2013-01-30 Abbott Biologicals B.V. Rescue of influenza virus
PT1861120T (pt) 2005-03-23 2016-08-18 Glaxosmithkline Biologicals Sa Utilização de um vírus influenza e de um adjuvante de emulsão óleo-em-água para induzir células t cd4 e/ou melhorar a resposta de células b de memória
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
RU2008101367A (ru) 2005-06-21 2009-08-10 Медиммун, Ллк (Us) Способы и композиции для экспрессии отрицательной смысловой вирусной рнк в собачьих клетках
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
CA2627971A1 (en) 2005-11-01 2007-05-10 Novartis Vaccines And Diagnostics Gmbh & Co Kg. Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment
US20100158943A1 (en) 2005-11-04 2010-06-24 Novartis Vaccines And Diagnostics Srl Administration routes for priming/boosting with influenza vaccines
US20090304742A1 (en) 2005-11-04 2009-12-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines with reduced amount of emulsion adjuvant
US9101578B2 (en) † 2006-05-01 2015-08-11 Technovax, Inc. Polyvalent influenza virus-like particle (VLP) compositions
HRP20140488T1 (hr) 2006-07-17 2014-07-04 Glaxosmithkline Biologicals S.A. Cjepivo protiv influence
US20080014217A1 (en) * 2006-07-17 2008-01-17 Emmanuel Jules Hanon Influenza vaccine
CL2008000747A1 (es) 2007-03-16 2008-04-25 Wyeth Corp Composicion de vacuna que comprende una primera y una segunda cepa inactivada del virus de la influenza aviar; metodo para vacunar un ave.

Also Published As

Publication number Publication date
AU2008331238B2 (en) 2014-03-27
JP2011504486A (ja) 2011-02-10
PL2211901T3 (pl) 2013-11-29
AU2014203436A1 (en) 2014-07-10
EP2211901A1 (en) 2010-08-04
WO2009068992A8 (en) 2013-09-12
KR20160079140A (ko) 2016-07-05
ES2755895T3 (es) 2020-04-24
AU2014203436B2 (en) 2016-11-17
PT2614835T (pt) 2019-11-27
ES2417495T5 (es) 2023-10-06
PT2211901E (pt) 2013-07-10
GB0810305D0 (en) 2008-07-09
KR20100108527A (ko) 2010-10-07
PL2211901T5 (pl) 2023-11-06
US20110189230A1 (en) 2011-08-04
CN101969995A (zh) 2011-02-09
HK1146577A1 (en) 2011-06-24
EP2211901B1 (en) 2013-05-01
NZ585674A (en) 2013-01-25
CA2706619A1 (en) 2009-06-04
AU2008331238A1 (en) 2009-06-04
CY1114762T1 (el) 2016-12-14
JP2014159454A (ja) 2014-09-04
SI2211901T1 (sl) 2013-08-30
EP2614835B1 (en) 2019-08-21
ES2417495T3 (es) 2013-08-08
US9669088B2 (en) 2017-06-06
EP2614835A1 (en) 2013-07-17
EP2211901B2 (en) 2023-04-26
JP2016155867A (ja) 2016-09-01
PL2614835T3 (pl) 2020-03-31
WO2009068992A1 (en) 2009-06-04
JP5957176B2 (ja) 2016-07-27
DK2211901T3 (da) 2013-07-08
HRP20130634T1 (hr) 2013-08-31
CA2706619C (en) 2015-05-19

Similar Documents

Publication Publication Date Title
DK2614835T3 (da) Vaccination med flere clader af H5 influenzavirus A
ZA201006934B (en) Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes
BRPI0821034A2 (pt) Vírus influenza modificado
DK3447131T3 (da) Influenza a-virusmutanter
DK2557520T3 (da) Bestemmelse af en nukleinsyresekvensubalance
CY2015012I2 (el) Αναστολεις του ιου της ηπατιτιδας c
DK3335728T3 (da) Biokemisk stabiliseret hiv-1 env-trimervaccine
DK2398794T3 (da) Hæmmere af hepatitis C-virus
EP2671451A4 (en) VIRENINAKTIVATOR
BRPI0716536A2 (pt) produÇço de vacinas de vÍrus influenza, sem a utilizaÇço de ovos
PT3141252T (pt) Inibidores da replicação do vírus influenza
PL2491152T3 (pl) Sposób stosowania zawiesinowego pieca do wytapiania, zawiesinowy piec do wytapiania, oraz palnik do koncentratu
SI3567124T1 (sl) Razreševanje frakcij genoma z uporabo števila polimorfizmov
DK2317851T3 (da) Anvendelse af 5-fluorcytosin som fungicid
DK2049559T3 (da) Forbedrede HPV vacciner
EP2442747A4 (en) DENTAL BRACES
EP2118323A4 (en) DETECTION OF INFLUENZA VIRUS
EP2446026A4 (en) TRANSAMINASEREAKTIONEN
ZA200809056B (en) Influenza virus vaccine
SMT201400170B (it) Vaccino contro hpv
EP2486054A4 (en) Recombinant antibodies against h1n1 influenza
DK2422810T3 (da) Influenzavaccine
DK2450492T3 (da) Anlæg til fastgørelse af en sanitetsgenstand
FI20090030A0 (fi) Onkolyyttiset virukset
EP2368899B8 (en) Avian influenza vaccine